In order to join the earning call, dial the conference’s bridge and key in the PIN code. Contact pSivida Corp for this information

More and more companies choose to conduct their earnings calls through conference calls and online meetings and it’s important to keep up to date with all relevant information.Need a conference calls service solution? Try QCONF conferencing today, Sign up now and get 5 free conference calls (no credit card required)

We develop sustained-release drug delivery products primarily for the treatment of chronic eye diseases. Our products deliver drugs at a controlled and steady rate for months or years. We have developed three of only four sustained-release products approved by the United States (U.S.) Food and Drug Administration (FDA) for treatment of back-of-the-eye diseases. Medidur(TM) for posterior segment uveitis, our lead product candidate, is in pivotal Phase 3 clinical trials, and ILUVIEN® for diabetic macular edema (DME), our lead licensed product, is sold in the U.S. and three European Union (EU) countries. Our product development program is focused primarily on utilizing our two core technology platforms to deliver drugs and biologics to treat chronic diseases. Our strategy includes developing products independently while continuing to leverage our technology platforms through collaborations and license agreements as appropriate.